OKC VeloCity | Revolutionary treatment to reverse blindness now offered in Oklahoma City

Revolutionary treatment to reverse blindness now available in Oklahoma City

By Kelly Dexter / Inside OKC / August 25, 2023

The Dean McGee Eye Institute (DMEI) is working with OU Health to administer a cutting-edge treatment to reverse vision loss in some patients. DMEI is one of just 17 centers in the U.S. certified to provide it. This treatment marks a significant milestone in the battle against Leber Congenital Amaurosis (LCA), a leading cause of inherited blindness in children. 

Shedding Light on LCA 

LCA is primarily caused by mutations in the RPE-65 genes. These mutations set in motion a cascade of events, resulting in the degeneration of retinal cells and a progressive loss of vision. Children with mutations in both copies of the RPE-65 gene begin to experience vision loss as early as five years old that worsens as they age, eventually leading to legal blindness. 

However, there is a glimmer of hope for those with functioning retinal cells remaining. LUXTURNA, an innovative gene therapy, offers a chance to reverse vision loss. It uses a harmless virus to deliver a normal copy of the RPE-65 gene to the retinal cells, enabling them to produce the necessary proteins and restore their ability to preserve and improve visual function. 

A Beacon of Hope in Oklahoma City 

DMEI has partnered with OU Health Pharmacy and the OU Health-Outpatient Surgery Center to offer the new treatment. Vitreoretinal surgeons, Dr. Razek G. Coussa, and Dr. Vinay A. Shah will lead the program. 

"Previously, patients in our area who qualified for LUXTURNA would have had to travel to other states to receive treatment. We are excited to now be able to offer this treatment right here in Oklahoma City," said Dr. Coussa. 

The accessibility of this treatment wouldn’t be possible without a generous contribution from Christian Kanady, founding partner of the Echo investment firm. His donation enabled DMEI to purchase the specialized visual function equipment they needed to provide the treatment. 

“The Dean McGee Eye Institute continues to put Oklahoma City on the map as a leader in specialized vision care and cutting-edge treatments. Providing this transformational vision loss reversal therapy will only add to their incredible impact locally and nationally," said Kanady. 

A Glimpse into the Future 

LUXTURNA certification is just the beginning of DMEI's ambitious plan to establish a center of excellence dedicated to providing essential medical and surgical treatments for patients with LCA. The vision includes conducting major national and international clinical trials at DMEI/OU. This center will be the first of its kind in Oklahoma and is envisioned to attract researchers, clinicians, and patients from all over the world.